People with strabismus, myopia, amblyopia, and other common eye conditions are 40% more likely to develop attention-deficit/hyperactivity disorder (ADHD) than those ...

Drug development for neurodegenerative diseases is struggling with one of its most intractable barriers: the slow, variable, and subjective nature of clinical endpoints Traditional assessment scales, ...

Researchers have developed a novel synthetic protein to treat macular degeneration and other incurable eye diseases that lead to blindness in millions of people. It is the first drug of its kind and ...

Combining artificial intelligence and genetics has allowed researchers to study the part of the eye that gives us sharp central vision in amazing detail for the first time. Subscribe to our newsletter ...

For some degenerative vision disorders, the therapies available don’t restore sight, they mainly slow its decline. To realize this benefit, a patient must receive an eye injection as frequently as ...

According to different studies done globally, about 80 per cent of blindness is avoidable if diagnosed and treated early. Thus, paediatric eye care service plays a vital role in the elimination of ...

The Ocular Neurobiology laboratory at the Institute for Neurosciences, a joint center of Miguel Hernández University (UMH) in Elche and the Spanish National Research Council (CSIC), is participating ...

Treatment shows potential to slow the progression of human degenerative eye diseases, including retinitis pigmentosa. Researchers at the National Institutes of Health (NIH) have developed eye drops ...

Semaglutide showed no significant association with increased risk of eye disorders or diabetic retinopathy in the meta-analysis. A potential link between semaglutide and increased risk of NAION was ...